These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 21660558)

  • 1. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women.
    Chung YE; Lee SH; Lee SY; Kim SY; Kim HH; Mirza FS; Lee SK; Lorenzo JA; Kim GS; Koh JM
    Osteoporos Int; 2012 Apr; 23(4):1235-43. PubMed ID: 21660558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
    Ishtiaq S; Fogelman I; Hampson G
    J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
    Polyzos SA; Anastasilakis AD; Bratengeier C; Woloszczuk W; Papatheodorou A; Terpos E
    Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass.
    Downs RW; Moffett AM; Ghosh A; Cox DA; Dowsett SA; Harper K
    Osteoporos Int; 2010 Jul; 21(7):1215-26. PubMed ID: 19798460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating sclerostin and estradiol levels are associated with inadequate response to bisphosphonates in postmenopausal women with osteoporosis.
    Morales-Santana S; Díez-Pérez A; Olmos JM; Nogués X; Sosa M; Díaz-Curiel M; Pérez-Castrillón JL; Pérez-Cano R; Torrijos A; Jodar E; Rio LD; Caeiro-Rey JR; Reyes-García R; García-Fontana B; González-Macías J; Muñoz-Torres M
    Maturitas; 2015 Dec; 82(4):402-10. PubMed ID: 26358930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model.
    Lee YS; Gupta R; Kwon JT; Cho DC; Seo YJ; Seu SY; Park EK; Han I; Kim CH; Sung JK; Kim KT
    Spine J; 2018 Oct; 18(10):1877-1887. PubMed ID: 29793000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin.
    Gatti D; Viapiana O; Adami S; Idolazzi L; Fracassi E; Rossini M
    Bone; 2012 Mar; 50(3):739-42. PubMed ID: 22178539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
    Catalano A; Morabito N; Basile G; Brancatelli S; Cucinotta D; Lasco A
    J Clin Endocrinol Metab; 2013 May; 98(5):1911-5. PubMed ID: 23596142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
    Meunier PJ; Vignot E; Garnero P; Confavreux E; Paris E; Liu-Leage S; Sarkar S; Liu T; Wong M; Draper MW
    Osteoporos Int; 1999; 10(4):330-6. PubMed ID: 10692984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women.
    Delmas PD; Davis SR; Hensen J; Adami S; van Os S; Nijland EA
    Osteoporos Int; 2008 Aug; 19(8):1153-60. PubMed ID: 18256777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
    Bachmann G; Kriegman A; Gonçalves J; Kianifard F; Warren M; Simon JA
    Menopause; 2011 Aug; 18(8):851-6. PubMed ID: 21796066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone.
    Piemonte S; Romagnoli E; Bratengeier C; Woloszczuk W; Tancredi A; Pepe J; Cipriani C; Minisola S
    J Endocrinol Invest; 2012 Oct; 35(9):866-8. PubMed ID: 22842667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-weekly teriparatide reduces serum sclerostin levels in postmenopausal women with osteoprosis.
    Ikeda T; Kaji H; Tamura Y; Akagi M
    J Orthop Sci; 2019 May; 24(3):532-538. PubMed ID: 30573396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies.
    Byrjalsen I; Leeming DJ; Qvist P; Christiansen C; Karsdal MA
    Osteoporos Int; 2008 Mar; 19(3):339-48. PubMed ID: 17846859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of SERMs on bone health. The effects of raloxifene on bone quality evaluated by hip structure analysis].
    Takada J; Iba K; Yamashita T; Yoshizaki T
    Clin Calcium; 2010 Mar; 20(3):355-63. PubMed ID: 20190365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of SERMs on bone health. SERM and metabolic markers of bone].
    Takami M; Shimada H
    Clin Calcium; 2010 Mar; 20(3):365-71. PubMed ID: 20190366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women.
    Drake MT; Srinivasan B; Mödder UI; Peterson JM; McCready LK; Riggs BL; Dwyer D; Stolina M; Kostenuik P; Khosla S
    J Clin Endocrinol Metab; 2010 Nov; 95(11):5056-62. PubMed ID: 20631014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide.
    Eastell R; Rogers A; Ni X; Krege JH
    Osteoporos Int; 2011 Jun; 22(6):1927-34. PubMed ID: 20838771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of anti-resorptive agents on trabecular bone score (TBS) in older women.
    Krieg MA; Aubry-Rozier B; Hans D; Leslie WD;
    Osteoporos Int; 2013 Mar; 24(3):1073-8. PubMed ID: 23052939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.